Patents Assigned to Board of Regents, Univ. of Texas
  • Patent number: 6040340
    Abstract: A method is provided for the improvement of implantation rates and/or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amount of(a) a nitric oxide synthase substrate, a nitric oxide donor, or both, optionally in combination with(b) a progestin, and,(c) optionally, in further combination with an estrogen.A method is also provided for fertility control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk for becoming pregnant an effective amount of nitric oxide synthase inhibitor in combination with an antiprogestin. Pharmaceutical compositions are also provided.
    Type: Grant
    Filed: May 7, 1996
    Date of Patent: March 21, 2000
    Assignees: Schering Aktiengesellschaft, The Board of Regents, Univ. of Texas System
    Inventors: Krzysztof Chwalisz, Robert E. Garfield
  • Patent number: 5811233
    Abstract: A psoriasis susceptibility locus defined as among linked members within a family has been identified. The locus is linked to an intron of the interleukin enhancer binding factor gene in some families, while being linked to an interleukin 8 gene in other families demonstrating a familial linked form of psoriasis. The locus identified may be further defined as being located distal to genetic maker D17S784 of human chromosome 17q. This locus does not demonstrate linkage with DNA markers within flanking the HLA cluster of genes. A psoriasis susceptibility locus has also been observed close to the centromere of human chromosome 4. Both identified regions provide positive LOD scores with markers on chromosomes 17q and particularly 2 regions close to the ILF gene or the interleukin 8 gene. Methods of screening a family for psoriasis susceptibility using a defined familial psoriasis susceptibility locus are also disclosed.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: September 22, 1998
    Assignee: Board of Regents, Univ. of Texas System
    Inventors: Anne Bowcock, James Tomfohrde, Alan Menter, Richard Gaynor
  • Patent number: 5785868
    Abstract: Sodium and borate ions are separated in supercritical water by addition of dissolved CO.sub.2 to cause precipitation of carbonates and the formation of boric acid. Carbonates and boric acid are then recovered as separate products.
    Type: Grant
    Filed: September 11, 1995
    Date of Patent: July 28, 1998
    Assignee: Board of Regents, Univ. of Texas System
    Inventors: Lixiong Li, Earnest F. Gloyna
  • Patent number: 5776751
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 7, 1998
    Assignees: Regeneron Pharmaceuticals, Inc., Board of Regents, Univ Of Texas
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
  • Patent number: 5678162
    Abstract: A mold useful for injection molding, comprising: a porous network of metal and oxidized metal and a cured epoxy resin dispersed in the porous network. The mold can be prepared by a process comprising the sequential steps of (a) forming a mixture of a metal powder and a polymer binder; (b) heating the mixture at a temperature in the range from about 100.degree. C. to about 300.degree. C. to remove a majority of the polymer binder from the mixture; (c) heating the mixture resulting from step (b) at a temperature greater than about 300.degree. C. and less than the melting point of the metal in the presence of oxygen to oxidize at least a portion of the metal to form a self-adhering porous network of metal and oxidized metal; (d) contacting the self-adhering porous network with an epoxy resin to fill at least a portion of the porous network with epoxy resin; and (e) curing the body resulting from step (d) to form the mold. The shape of the mold can be performed by selective laser sintering of the mixture.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: October 14, 1997
    Assignee: Board of Regents, Univ. of Texas System
    Inventors: Joel W. Barlow, Balasubramanian Badrinarayan, Joseph J. Beaman, David L. Bourell, Richard H. Crawford, Harris L. Marcus, James R. Tobin, Neal K. Vail
  • Patent number: 5595904
    Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.
    Type: Grant
    Filed: January 3, 1994
    Date of Patent: January 21, 1997
    Assignees: Board of Regents, Univ. of Texas, Regeneron Pharmaceuticals, Inc.
    Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
  • Patent number: 5580543
    Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 3, 1996
    Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.
    Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
  • Patent number: 5565552
    Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 15, 1996
    Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.
    Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
  • Patent number: 5492697
    Abstract: A biodegradable implant for placement in nonunion bone fractures as a substitute for bone graft material is provided which is a flat plate or disk having a thickness of between about 1 mm and about 15% of the length of the bone, interconnected micropores, and canals substantially equivalent in size and spacing to naturally-occurring Haversian canals. The implant may additionally comprise additives such as growth factors, including bone morphogenic protein. In a preferred embodiment the implant is formed from a biodegradable polymer such as a polylactic acid-polyglycolic acid copolymer by a gel casting technique followed by solvent extraction to precipitate the implant as a microporous solid.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: February 20, 1996
    Assignee: Board of Regents, Univ. of Texas System
    Inventors: Barbara D. Boyan, Chandra M. Agrawal, James D. Heckman
  • Patent number: 4823807
    Abstract: Arthritis and related diseases are diagnosed by recording sound from a joint moving against a predefined resistance or a controlled velocity, and correlating the acoustic amplitude and instantaneous frequency with the joint angle.
    Type: Grant
    Filed: February 11, 1988
    Date of Patent: April 25, 1989
    Assignee: Board of Regents, Univ. of Texas System
    Inventors: I. Jon Russell, Thomas C. Carlson, Gilbert A. Vipraio
  • Patent number: 4774085
    Abstract: The present invention relates to pharmaceutical administration systems containing phosphatidylserine and phosphatidylcholine or phosphatidylethanolamine derivatives in the form of liposomes which encapsulate water soluble muramyldipeptide derivatives in combination with gamma-interferon. The liposomes are prepared by conventional dispersion methods. The pharmaceutical administration systems when applied in the form of liposomes are especially useful in the cancer chemotherapy for combating metastatic tumor cells.
    Type: Grant
    Filed: July 9, 1985
    Date of Patent: September 27, 1988
    Assignee: 501 Board of Regents, Univ. of Texas
    Inventor: Isaiah J. Fidler
  • Patent number: 4621561
    Abstract: A switch for use in an inductive energy store transfer circuit utilizes a quantity of electrically conductive liquid bidirectionally flowable between a position that establishes electrical connection between electrodes and a position that opens electrical connection between the electrodes. High pressure gas biases the liquid to a position that establishes electrical connection between the electrodes, and yieldably resists movement of the liquid toward the position that opens electrical connection between the electrodes. Current through the switch electrodes produces a magnetic force that acts on the liquid and urges it toward the position that opens electrical connection between the electrodes. Switching action occurs upon a predetermined magnitude of current being attained.
    Type: Grant
    Filed: June 22, 1983
    Date of Patent: November 11, 1986
    Assignee: Board of Regents, Univ. of Texas System
    Inventor: William F. Weldon